N/A N=269 Evaluation of a Systematic Approach to Weaning From Mechanical Ventilation
Weaning Failure · Complication of Respirator [Ventilator]
Primary: Mortality — 10; 14 participants — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=45 Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
Acute Myelogenous Leukemia
Primary: Number of Participants With Relapse-Free Response at 1 Year — 10; 10 participants
Phase 2 N=60 CFAR Study in Patients With Chronic Lymphocytic Leukemia
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Phase 2 N=50 Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Burkitt's Lymphoma · Lymphoblastic Lymphoma · Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose for Cyclophosphamide (MTD) — 200 mg/m^2
Phase 4 N=20 Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
HIV
Primary: Change in Peak Oxygen Uptake. — 2.2; 2.8 ml/Kg/min — p=<0.05
Phase 1 N=200 Oral Tolerability Of Two Nicotine Dosage Forms
Healthy Volunteer Smokers
Primary: Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 1 — 2.3; 12.6 Percentage
Phase 3 N=40 Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin
Intraoperative Complications · Thermal Injury · Electrocoagulation
Primary: Histologic Thermal Injury to Epigastric Port Site Skin — 1; 7 participants
N/A N=128 Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds
Heart Failure · Ventricular Arrythmias
Primary: Percentage of Participants Free of System-related Complications at 3-months Post Implant — 93.6 Percentage of Participants
Phase 4 N=40 Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK
Myopia · Astigmatism
Primary: 1 Day Postoperative Lasik Uncorrected Visual Acuity — -0.04; -0.05; 0.06 LogMar
N/A N=60 Stage 1 Treatment Development With Homeless Mothers
Substance Abuse
Primary: Percent Days of Substance Use in the Prior 3 Months. — 45.40; 49.17 percent days of substance use
N/A N=13 Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Lung Cancer
Primary: Two Year Progression Free Survival Rate — 8 participants
Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects
Phase 1 N=40 A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
Psoriasis
Primary: Change From Baseline in Composite Gene Expression Score Based on IL-12 Pathway Related Interferon Gamma (IFN-γ)-Modulated Genes in Psoriatic Lesions of Participants…
Phase 1 N=47 CP-751,871 Treatment For Patients With Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — NA mg/kg
Phase 4 N=361 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs
Focal Epilepsy
Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…